A Study Testing a New Heart Scan Method to Improve Pacemaker Treatment for Heart Failure

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKing's College London

About this trial

Cardiac resynchronization therapy (CRT) is a device treatment for patients with heart failure which cannot be managed by medications alone. CRT can help the heart contract more efficiently and improve the pumping function. However, many patients do not benefit from this treatment. Therefore, a better selection tool will help us to determine the most suitable patients to receive this treatment. A new measure of pumping function of the heart called: first-phase ejection fraction or EF1 has been shown a good tool to select suitable patients for CRT. EF1 is a sensitive measurement of heart function and can be easily measured by echocardiography (an ultrasound heart scan).

The purpose of this study is to examine whether this new measurement (EF1) can predict outcomes and response to CRT treatment.

Eligibility criteria

Qualifiers

Age 18 years or older

On optimal medical therapy for heart failure

NYHA class II to IV

Left ventricular ejection fraction (EF) ≤ 35%

Disqualifiers

Co-morbidities likely to reduce life expectancy to less than 6 months

Major cardiovascular event within the past 6 weeks

More than mild aortic stenosis

Receiving continuous or intermittent infusion therapy for heart failure

Trial design

Treatments tested in this trial

  • EF1 guided CRT optimisation
  • Standard of Care (SOC)

Treatment groups

400 Participants
are divided into 2 treatment groups

Sponsors and collaborators

King's College London

Lead sponsor

Guy's and St Thomas' NHS Foundation Trust

Collaborator

The Leeds Teaching Hospitals NHS Trust

Collaborator

King's College Hospital NHS Trust

Collaborator

Barts Helth NHS Trust

Collaborator